Brian Buck
Brian Buck is an expert in Neurology at University of Alberta Hospital (Canada). As of October 2026, ScienceLeadR ranks Brian Buck in the top 1% of experts worldwide for Cerebrovascular Disorders. Brian Buck has authored 298 publications, the most recent in 2026, and is an investigator in 31 clinical trials, 5 of them ongoing. SLR score: 1,207 (community average: 125). How the SLR is computed.
LeadR Profile
Neurology
Subspecialties: Cardiology - Medical Imaging
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2007 - 2026
Number : 298
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Effectiveness of Physical Rehabilitation Interventions on Walking Capacity and Wearable Sensor-Derived Performance After Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PMID 42515217 — exercise, stroke, rehabilitation, gait, walking speed, walking, wearables and biometrics sensors | Sensors (Basel) | 2026 | 0 |
| Radiological thrombus characteristics and the effect of tenecteplase versus alteplase on outcomes in acute ischemic stroke. PMID 42483867 — ischemic stroke, stroke, tissue plasminogen activator, tenecteplase | Int J Stroke | 2026 | 0 |
| Tenecteplase Efficacy in Patients With Distal Occlusions: Secondary Analysis of the TASTE Randomized Clinical Trial. PMID 42483807 — growth, stroke, tissue plasminogen activator, cerebral arteries, arteries, cerebrovascular circulation, posterior cerebral artery, odds ratio, anterior cerebral artery, cerebrovascular disorders, middle cerebral artery, tenecteplase, therapeutics, computed tomography angiography, taste | Stroke | 2026 | 0 |
| Safety and Efficacy of Nerinetide at Year 1 in Participants Enrolled in ESCAPE-NEXT: A Multicenter, Double-Blind, Randomized Controlled Trial. PMID 42333641 — heart diseases, safety, ischemic stroke, neuroprotection, therapeutics | J Am Heart Assoc | 2026 | 0 |
| Association of Successful Recanalization and Functional Outcomes in Minor Ischemic Stroke With Proven Occlusion: A Secondary Analysis of TEMPO-2 Trial. PMID 42318629 — ischemic stroke, stroke, tomography, cerebral arteries, angiography, odds ratio, tenecteplase, therapeutics, random allocation, computed tomography angiography | Stroke | 2026 | 0 |
Clinical Studies 31
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 4
Ongoing Clinical Trials
5 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial Part 2 NCT07227246 — cerebral hemorrhage, hemorrhage, blood, stroke, vaccines, hemorrhagic stroke, blood pressure, factor viia, therapeutics, biological products | Phase 3 | Recruiting | 2025 |
| ACT GLOBAL IA Thrombolysis(ACT REACT 004)Domain Within the ACT GLOBAL Adaptive Platform Trial NCT06352632 NCT07687056 — ischemic stroke, stroke, plasminogen, plasminogen activators, tissue plasminogen activator, multiple chronic conditions, fibrinolytic agents, reperfusion, tenecteplase, therapeutics, tissues, thrombectomy | Phase 3 | Recruiting | 2026 |
| NoNO 42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis With or Without Endovascular Thrombectomy NCT06403267 — safety, ischemic stroke, stroke, powders, neuroprotective agents, neuroprotection, reperfusion, cerebral infarction, thrombectomy, ischemia, male | Phase 2 | Recruiting | 2024 |
| ACT GLOBAL THROMBOLYSIS (ACT WHEN 001) Domain Within the ACT GLOBAL Adaptive Platform Trial NCT06352632 NCT06320431 — ischemic stroke, stroke, multiple chronic conditions, body weight, tenecteplase, therapeutics, thrombectomy, direct-acting oral anticoagulants | Phase 3 | Recruiting | 2024 |
| EndovaSCular TreAtment to imProve outcomEs for Medium Vessel Occlusions (ESCAPE MeVO Trial) NCT05151172 — safety, blood, ischemic stroke, stroke, pharmaceutical preparations, blood pressure, fibrinolytic agents, intracranial thrombosis, coagulants, therapeutics, thrombosis, thrombectomy, blood vessels | N/A | Active not recruiting | 2022 |
LeadR Networks
Main global connection map